GlassScriptPhysician profile
Shadi Latta
NPI 1427255447
$15,555.27
in general payments reported to CMS, 2019-2025
67 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,789 · 2020: $1,158 · 2021: $1,671 · 2022: $1,634 · 2023: $4,146 · 2024: $2,658 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,162 · Consulting Fee: $1,943 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,162.41 |
| Consulting Fee | $1,942.50 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,932.64 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Janssen Biotech, INC. | $2,215.56 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| Merck Sharp & Dohme LLC | $921.22 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $832.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $743.86 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $682.14 | 2019-2025 | |
| Incyte Corporation | $619.59 | 2019-2025 | Jakafi, Monjuvi |
| Genentech USA, INC. | $454.37 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Takeda Pharmaceuticals U.S.A., INC. | $394.00 | 2020-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Gilead Sciences, INC. | $393.55 | 2019-2025 | Trodelvy |
| Amgen INC. | $320.95 | 2020-2023 | Vectibix, Nplate, Xgeva |
| Regeneron Healthcare Solutions, INC. | $291.68 | 2022-2024 | Libtayo |
| Sobi, INC | $237.02 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $235.29 | 2019-2023 | Epkinly, Imbruvica |
| Glaxosmithkline, LLC. | $234.38 | 2022-2024 | Zejula, Jemperli, Ojjaara |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $213.71 | 2019-2025 | |
| Astellas Pharma US INC | $210.69 | 2022-2025 | Padcev, Xtandi, Vyloy |
| Abbvie INC. | $204.99 | 2019-2025 | |
| Lilly USA, LLC | $203.49 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Genzyme Corporation | $198.75 | 2019-2025 | |
| Seagen INC. | $197.33 | 2019-2023 | Padcev |
| Exelixis INC. | $174.74 | 2019-2024 | Cabometyx |
| Celgene Corporation | $155.03 | 2021-2025 | Pomalyst, Reblozyl, Recothrom |
| Eisai INC. | $143.70 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $142.15 | 2021-2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $139.08 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.78 | 2019-2024 | |
| Array Biopharma INC | $125.85 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Puma Biotechnology, INC. | $122.33 | 2019-2025 | |
| Beigene USA, INC. | $117.59 | 2023-2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $110.27 | 2020-2024 | Tavalisse, Rezlidhia |
| Tersera Therapeutics LLC | $109.66 | 2023-2025 | Xermelo, Zoladex |
| G1 Therapeutics, INC. | $104.84 | 2022-2023 | Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.13 | 2019-2021 | |
| Dova Pharmaceuticals | $92.80 | 2020-2021 | |
| Kite Pharma, INC. | $74.65 | 2021-2024 | Yescarta |
| Ge Healthcare | $60.32 | 2021-2024 | |
| Daiichi Sankyo INC. | $57.36 | 2023-2024 | Enhertu |
| Amneal Pharmaceuticals LLC | $53.73 | 2024-2025 | Alymsys, Avastin |
| Mirati Therapeutics, INC. | $50.02 | 2023-2024 | Krazati |
| Tempus Ai, INC | $45.96 | 2024 | |
| Morphosys, US INC. | $45.62 | 2023 | Monjuvi |
| Coherus Oncology, INC. | $45.41 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $45.02 | 2021-2025 | Xpovio |
| Myriad Genetic Laboratories, INC. | $44.25 | 2021-2023 | Myrisk |
| Janssen Pharmaceuticals, INC | $37.78 | 2021 | |
| Pharmacosmos Therapeutics INC. | $37.60 | 2024 | Cosela |
| Myovant Sciences INC. | $37.18 | 2021 | |
| Foundation Medicine, INC. | $28.77 | 2019 | |
| Genmab U.S., INC. | $27.89 | 2024 | Epkinly |
| Fortovia Therapeutics, INC. | $27.69 | 2020 | |
| Sumitomo Pharma America, INC. | $26.83 | 2023 | Orgovyx |
| Amag Pharmaceuticals, INC. | $26.77 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $26.30 | 2024 | Clonoseq |
| Dendreon Pharmaceuticals LLC | $24.63 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $24.33 | 2021 | |
| Eusa Pharma (US) LLC | $23.36 | 2021 | |
| Acrotech Biopharma INC. | $20.08 | 2021 | |
| Epizyme, INC. | $20.02 | 2022 | |
| Azurity Pharmaceuticals, INC. | $19.92 | 2025 | Danziten |
| Springworks Therapeutics, INC. | $18.88 | 2025 | Gomekli |
| Cti Biopharma Corp. | $18.62 | 2022 | |
| Clovis Oncology, INC. | $17.93 | 2019 | |
| Immunogen, INC. | $16.20 | 2024 | Elahere |
| Pharmaand Gmbh | $15.77 | 2025 | Rubraca |
| Tolmar, INC. | $15.77 | 2025 | Rubraca |
| Advanced Accelerator Applications | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadi Latta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.